BE2016C045I2 - - Google Patents

Info

Publication number
BE2016C045I2
BE2016C045I2 BE2016C045C BE2016C045C BE2016C045I2 BE 2016C045 I2 BE2016C045 I2 BE 2016C045I2 BE 2016C045 C BE2016C045 C BE 2016C045C BE 2016C045 C BE2016C045 C BE 2016C045C BE 2016C045 I2 BE2016C045 I2 BE 2016C045I2
Authority
BE
Belgium
Application number
BE2016C045C
Other languages
French (fr)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BE2016C045I2 publication Critical patent/BE2016C045I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BE2016C045C 2005-12-13 2016-08-31 BE2016C045I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74995305P 2005-12-13 2005-12-13
US80194806P 2006-05-19 2006-05-19

Publications (1)

Publication Number Publication Date
BE2016C045I2 true BE2016C045I2 (en) 2026-02-02

Family

ID=38008638

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C045C BE2016C045I2 (en) 2005-12-13 2016-08-31

Country Status (24)

Country Link
US (2) US7838638B2 (en)
EP (4) EP3366702B1 (en)
JP (1) JP5063612B2 (en)
KR (1) KR101158959B1 (en)
CN (1) CN101326195B9 (en)
AU (1) AU2006325860B2 (en)
BE (1) BE2016C045I2 (en)
BR (1) BRPI0619792B1 (en)
CA (1) CA2631938C (en)
CY (3) CY1113097T1 (en)
DK (2) DK2481753T3 (en)
EA (1) EA014298B1 (en)
ES (2) ES2389780T7 (en)
HR (2) HRP20120606T4 (en)
HU (2) HUE039353T2 (en)
IL (1) IL191217A (en)
LT (2) LT2481753T (en)
LU (1) LU93189I2 (en)
NO (2) NO340827B1 (en)
PL (2) PL1963368T6 (en)
PT (2) PT2481753T (en)
RS (2) RS52509B2 (en)
SI (2) SI1963368T1 (en)
WO (1) WO2007070750A1 (en)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1983000B1 (en) 2003-11-21 2015-09-02 UCB Biopharma SPRL Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
PL1963368T6 (en) * 2005-12-13 2021-02-08 Eli Lilly And Company Anti-il-17 antibodies
JP2009534297A (en) 2006-03-10 2009-09-24 ザイモジェネティクス， インコーポレイテッド Antibodies that bind to both IL-17A and IL-17F and methods of use thereof
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
NZ574804A (en) * 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
CN101688200B (en) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Sequence based engineering and optimization of single chain antibodies
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2009026412A1 (en) * 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
BRPI0908312A2 (en) 2008-05-05 2015-08-18 Novimmune Sa '' Isolated fully human monoclonal antibody, pharmaceutical composition, symptom-relieving method of a clinical indication, and method of relieving a symptom of an autoimmune disease, inflammatory disorder or cell proliferation disorder ''
CA2737636A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
JP2012508563A (en) * 2008-11-12 2012-04-12 シェーリング コーポレイション ΒG1-IGG intron for enhanced anti-IGF1R expression
US8211434B2 (en) * 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
US20110223169A1 (en) * 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
WO2011053763A2 (en) 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2012018767A2 (en) * 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
TW201302793A (en) * 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
MX356279B (en) * 2010-10-08 2018-05-22 Novartis Ag Star Methods of treating psoriasis using il-17 antagonists.
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
PH12013501435B1 (en) 2011-01-14 2019-02-01 UCB Biopharma SRL Antibody molecules which bind il-17a and il-17f
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Composition for treating rheumatoid arthritis and method of use thereof
RU2014125071A (en) 2011-11-21 2015-12-27 Новартис Аг METHODS FOR TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE ALLELEES OR NO PSA RESPONSE
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
CA2866128C (en) 2012-03-07 2017-02-28 Eli Lilly And Company Il-17 antibody formulation
AR090626A1 (en) * 2012-04-20 2014-11-26 Lilly Co Eli ANTI-BAFF-ANTI-IL-17 BIESPECIFIC ANTIBODIES
CN104244979A (en) 2012-04-20 2014-12-24 诺华股份有限公司 Methods of treating ankylosing spondylitis using IL-17 antagonists
AR091116A1 (en) 2012-05-22 2015-01-14 Bristol Myers Squibb Co BISPECIFIC ANTIBODIES AND THEIR METHODS OF USE
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
CN104936618A (en) 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 Humanized monoclonal antibodies against activated protein c and uses thereof
LT2953969T (en) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
TW201444867A (en) * 2013-03-08 2014-12-01 Lilly Co Eli Anti-TNF-anti-IL-17 bispecific antibodies
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20150004133A1 (en) * 2013-06-07 2015-01-01 The Regents Of The University Of California Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
US9862765B2 (en) 2013-11-18 2018-01-09 Shanghai Hengrui Pharmaceutical Co., Ltd. IL-17A binding agent and uses thereof
AU2014370875B2 (en) * 2013-12-27 2017-11-23 Osaka University Vaccine targeting IL-17A
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP2017507939A (en) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド Anti-IL-13 / IL-17 bispecific antibody and use thereof
RU2577228C2 (en) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Anti-il-17 antibodies, methods of their production and application
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists
FI3191120T3 (en) 2014-09-10 2024-07-10 Novartis Ag THE USE OF IL-17 ANTAGONISTS TO PREVENT THE PROGRESSION OF STRUCTURAL DAMAGE IN PATIENTS WITH PSORIASIS
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
KR20240110106A (en) 2015-01-12 2024-07-12 애피바디 에이비 Il-17a-binding polypeptides
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN106336459B (en) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 Human interleukin-17A resisting monoclonal antibody, preparation method and application thereof
KR20180017145A (en) 2015-07-16 2018-02-20 일라이 릴리 앤드 캄파니 Treatment of pruritus
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN108495651A (en) 2015-12-17 2018-09-04 诺华股份有限公司 The antibody molecule and application thereof of anti-PD-1
JP7014724B2 (en) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド Tandem-type Fab immunoglobulin and its use
CN107488227A (en) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 Anti-human IL-17 A monoclonal antibodies, its preparation method and application
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
EP3487881B1 (en) 2016-07-19 2024-08-21 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
TN2019000082A1 (en) 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof
JP2019505516A (en) 2016-11-28 2019-02-28 ノバルティス アーゲー Method of treating acne using an interleukin-17 (IL-17) antagonist
CN116715775A (en) 2017-02-10 2023-09-08 豪夫迈·罗氏有限公司 Anti-tryptase antibodies, compositions thereof and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
KR102321861B1 (en) * 2017-03-10 2021-11-05 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 Monoclonal antibodies against both IL-17A and IL-17F and uses thereof
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
WO2018236728A1 (en) 2017-06-18 2018-12-27 Kindred Biosciences, Inc. Il17a antibodies and antagonists for veterinary use
WO2019027828A1 (en) 2017-08-04 2019-02-07 Eli Lilly And Company Anti-il-17 antibody dose regimen
EP3672988A1 (en) 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
AU2018361975A1 (en) 2017-11-02 2020-05-07 Novartis Ag Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
KR102048475B1 (en) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 Antibodies Specifically Binding Against IL-17A and Uses Thereof
EP3712170A4 (en) * 2017-11-10 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
MX2020005651A (en) 2017-11-30 2020-10-28 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof.
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
CN112074541A (en) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins prepared therefrom
JP6930778B2 (en) * 2018-05-17 2021-09-01 江蘇▲筌▼信生物医薬有限公司Ｑｙｕｎｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． Anti-human interleukin 17A monoclonal antibody and its use
CN110551215A (en) 2018-05-30 2019-12-10 中山康方生物医药有限公司 Anti-interleukin-17A antibody, pharmaceutical composition and use thereof
PE20210320A1 (en) 2018-06-01 2021-02-16 Novartis Ag BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
KR20260109977A (en) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. Methods and compositions for treating subjects having rheumatoid arthritis
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CN111018974B (en) * 2018-10-10 2022-04-01 东莞市朋志生物科技有限公司 Recombinant antibody of anti-human cardiac troponin I
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
CN109369806B (en) * 2019-01-14 2019-04-19 迈威(上海)生物科技有限公司 The minimizing technology of cysteine variant in Su Jin monoclonal antibody product
JP7542543B2 (en) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー Anti-IL-6 receptor antibodies for treating juvenile idiopathic arthritis - Patents.com
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP7525499B2 (en) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト Multispecific antibodies with specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereof
PE20212185A1 (en) 2019-02-18 2021-11-11 Lilly Co Eli FORMULATION OF THERAPEUTIC ANTIBODIES
JP2022545312A (en) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー Methods of diagnosis and treatment of rheumatoid arthritis
KR102400401B1 (en) * 2019-05-22 2022-05-24 (주)셀인바이오 Anti-inflammatory peptide and anti-inflammatory composition
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
ES3059248T3 (en) 2019-07-26 2026-03-19 Sinocelltech Ltd Humanized anti-il17a antibody and use thereof
WO2021018191A1 (en) 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Method for treating autoimmune disease by il-17 antagonist
EP4031570A1 (en) 2019-09-20 2022-07-27 Novartis AG Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2021099924A1 (en) 2019-11-19 2021-05-27 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
JP2023504679A (en) 2019-12-06 2023-02-06 ノバルティス アーゲー Methods of treating lichen planus using interleukin-17 (IL-17) antagonists
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
EP4077349A1 (en) 2019-12-16 2022-10-26 BicycleTX Limited Bicyclic peptide ligands specific for il-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
MX2022014925A (en) 2020-05-27 2023-01-04 Sanofi Sa IL-17A MODULATORS.
EP4157828A1 (en) 2020-05-27 2023-04-05 Sanofi Il-17a modulators
US20230235041A1 (en) 2020-06-23 2023-07-27 Novartis Ag Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
CN115746132B (en) * 2021-09-03 2023-09-08 三优生物医药(上海)有限公司 anti-IL-17A antibodies and uses thereof
IT202100023816A1 (en) * 2021-09-16 2023-03-16 Takis S R L Antibody against SARS-CoV-2 and its uses in the medical field.
CN113896793B (en) * 2021-09-30 2023-05-26 港科鹏禾生物(苏州)有限公司 Monoclonal antibody for resisting human IL-17RC and application thereof
JP2025516772A (en) 2022-05-16 2025-05-30 ノバルティス アーゲー Methods of treating giant cell arteritis with interleukin-17 (IL-17) antagonists - Patents.com
AU2023270497A1 (en) 2022-05-18 2024-12-05 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
JP2026500183A (en) 2022-12-09 2026-01-06 サノフイ therapeutic compounds
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025104230A1 (en) 2023-11-17 2025-05-22 Sanofi Benzoxazoles as modulators of il-17a
WO2025248073A1 (en) 2024-05-30 2025-12-04 Sanofi Therapeutic compounds
TW202617180A (en) * 2024-06-20 2026-05-01 南韓商賽特瑞恩股份有限公司 Stable pharmaceutical preparations
CN120249218B (en) * 2024-10-15 2026-03-20 武汉纺织大学 A hybridoma cell line secreting broad-spectrum monoclonal antibodies against micro/nanoplastics and its applications

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US539A (en) 1837-12-26 Standard measurer for taking measure for coats
US5225A (en) 1847-08-07 Latch
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimeric animal and method for producing the same
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1983000B1 (en) 2003-11-21 2015-09-02 UCB Biopharma SPRL Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1963368T6 (en) 2005-12-13 2021-02-08 Eli Lilly And Company Anti-il-17 antibodies

Also Published As

Publication number Publication date
DK1963368T3 (en) 2012-08-06
CN101326195A (en) 2008-12-17
IL191217A (en) 2015-10-29
EP2481753A1 (en) 2012-08-01
HUS1600037I1 (en) 2016-10-28
US20080269467A1 (en) 2008-10-30
KR101158959B1 (en) 2012-07-09
CY1113097T1 (en) 2016-04-13
PL1963368T3 (en) 2012-11-30
PL2481753T3 (en) 2018-09-28
EP3366702A1 (en) 2018-08-29
EP1963368B1 (en) 2012-07-18
CY2016030I2 (en) 2016-12-14
CY1120365T1 (en) 2019-07-10
CN101326195B (en) 2012-01-11
HRP20120606T1 (en) 2012-10-31
CN101326195B9 (en) 2022-11-11
HUE039353T2 (en) 2018-12-28
ES2389780T3 (en) 2012-10-31
ES2672221T3 (en) 2018-06-13
AU2006325860A1 (en) 2007-06-21
LT2481753T (en) 2018-05-25
RS52509B (en) 2013-04-30
HK1120275A1 (en) 2009-03-27
DK2481753T3 (en) 2018-06-18
PL1963368T6 (en) 2021-02-08
HRP20120606T4 (en) 2020-08-07
KR20080068122A (en) 2008-07-22
NO2017044I1 (en) 2017-08-18
PT1963368E (en) 2012-09-14
EP3366702B1 (en) 2023-08-09
LU93189I2 (en) 2016-10-31
NO340827B1 (en) 2017-06-26
US8110191B2 (en) 2012-02-07
EP1963368A1 (en) 2008-09-03
BRPI0619792A2 (en) 2011-10-18
EA014298B1 (en) 2010-10-29
CY2016030I1 (en) 2016-12-14
US20110027290A1 (en) 2011-02-03
NO2017044I2 (en) 2017-08-18
JP2009519348A (en) 2009-05-14
EP1963368B3 (en) 2020-06-10
CA2631938A1 (en) 2007-06-21
EA200870050A1 (en) 2009-12-30
EP3808769A1 (en) 2021-04-21
RS52509B2 (en) 2020-09-30
DK1963368T6 (en) 2020-06-29
PT2481753T (en) 2018-07-13
EP2481753B1 (en) 2018-04-18
JP5063612B2 (en) 2012-10-31
SI1963368T1 (en) 2012-11-30
LTC1963368I2 (en) 2018-01-10
SI2481753T1 (en) 2018-06-29
HRP20180941T1 (en) 2018-08-10
US7838638B2 (en) 2010-11-23
WO2007070750A1 (en) 2007-06-21
LTPA2016026I1 (en) 2016-09-26
RS57255B1 (en) 2018-08-31
BRPI0619792B1 (en) 2021-09-28
ES2389780T7 (en) 2021-01-14
CA2631938C (en) 2014-05-20
NO20082905L (en) 2008-09-03
AU2006325860B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
BE2025C533I2 (en)
BE2023C529I2 (en)
BE2021C552I2 (en)
BE2021C557I2 (en)
BE2021C524I2 (en)
BE2021C519I2 (en)
BE2020C531I2 (en)
BE2020C511I2 (en)
BE2020C508I2 (en)
BE2019C521I2 (en)
BE2019C503I2 (en)
BE2018C037I2 (en)
BE2018C019I2 (en)
BE2017C028I2 (en)
BE2019C533I2 (en)
BE2018C028I2 (en)
BE2017C007I2 (en)
BE2016C022I2 (en)
BE2015C074I2 (en)
BE2014C012I2 (en)
BE2014C057I2 (en)
BE2013C074I2 (en)
BE2013C014I2 (en)
BE2012C042I2 (en)
BE2012C028I2 (en)